BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Cytarabine

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

297+ PubMed studies analyzed · 28 RCTs · Evidence Score: 50.4

Research Domains

Cytarabine has been studied across 15 research domains including 🔬 Oncology, 😴 Sleep, 🫁 Liver & Detox, 🔬 Inflammation, ⏳ Longevity & Aging. The primary research focus is 🔬 Oncology with 35% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Cytarabine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Trifluridine
16 shared targets
Melphalan
20 shared targets
Thioinosine
11 shared targets
Ciclopirox
15 shared targets
Methotrexate
21 shared targets
lidoflazine
15 shared targets
Azathioprine
14 shared targets
Betamethasone
10 shared targets
Lumefantrine
10 shared targets
Mycophenolic
12 shared targets
Loading evidence profile...

This evidence profile for Cytarabine is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.